A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

NCT01983501 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2 Positive Breast Cancers

Interventions

DRUG: Tucatinib (ONT-380)
DRUG: T-DM1

Sponsor

Seagen Inc.